Literature DB >> 35369701

Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAAO Registry.

Matthew J Price1, Miguel Valderrábano2, Sarah Zimmerman3, Daniel J Friedman4, Saibal Kar5, Jeptha P Curtis3,6, Frederick A Masoudi7, James V Freeman3,6.   

Abstract

BACKGROUND: Pericardial effusion (PE) is a potential complication of transcatheter left atrial appendage occlusion. The objective of this study was to investigate the incidence, associated characteristics, and outcomes of PE following left atrial appendage occlusion.
METHODS: Patients in the NCDR LAAO Registry who underwent a Watchman procedure between January 1, 2016 and December 31, 2019 were included. The primary outcome was in-hospital PE requiring intervention (percutaneous drainage or surgery). Odds ratios (ORs) were calculated for adverse event rates associated with PE.
RESULTS: The study population consisted of 65 355 patients. The mean patient age was 76.2±8.1 years, and the mean CHA2DS2-VASc score was 4.6±1.5. PE occurred in 881 patients (1.35%). Clinical variables independently associated with PE included older age, female sex, left ventricular function, paroxysmal atrial fibrillation, prior bleeding, lower serum albumin, and preprocedural dual antiplatelet therapy; procedural variables included number of delivery sheaths used, sinus rhythm during the procedure, and moderate sedation rather than general anesthesia. PE was associated with increased risk of in-hospital stroke (OR, 6.58 [95% CI, 3.32-13.06]; P<0.0001), death (OR, 56.88 [95% CI, 39.79-81.32]; P<0.0001), and the composite of death, stroke, or systemic embolism (OR, 28.64 [95% CI, 21.24-38.61]; P<0.0001). PE during the index hospitalization was associated with increased risk of death (OR, 3.52 [95% CI, 2.23-5.54]; P<0.0001) and the composite of death, stroke, or systemic embolism (OR, 3.42 [95% CI, 2.31-5.07]; P<0.0001) between discharge and 45-day follow-up.
CONCLUSIONS: In-hospital PE during transcatheter left atrial appendage occlusion is infrequent but associated with a substantially higher risk of adverse events, including in-hospital and early postdischarge mortality. Strategies to minimize PE are critical to improve the risk-benefit ratio for this therapy.

Entities:  

Keywords:  anticoagulants; atrial fibrillation; pericardial effusion

Mesh:

Year:  2022        PMID: 35369701      PMCID: PMC9132377          DOI: 10.1161/CIRCINTERVENTIONS.121.011718

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   7.514


  13 in total

Review 1.  Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies.

Authors:  Apostolos Tzikas; David R Holmes; Sameer Gafoor; Carlos E Ruiz; Carina Blomström-Lundqvist; Hans-Christoph Diener; Riccardo Cappato; Saibal Kar; Randal J Lee; Robert A Byrne; Reda Ibrahim; Dhanunjaya Lakkireddy; Osama I Soliman; Michael Näbauer; Steffen Schneider; Johannes Brachman; Jeffrey L Saver; Klaus Tiemann; Horst Sievert; A John Camm; Thorsten Lewalter
Journal:  EuroIntervention       Date:  2016-05-17       Impact factor: 6.534

2.  Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device: Results From the PINNACLE FLX Trial.

Authors:  Saibal Kar; Shephal K Doshi; Ashish Sadhu; Rodney Horton; Jose Osorio; Christopher Ellis; James Stone; Manish Shah; Srinivas R Dukkipati; Stuart Adler; Devi G Nair; Jamie Kim; Oussama Wazni; Mathew J Price; Federico M Asch; David R Holmes; Robert D Shipley; Nicole T Gordon; Dominic J Allocco; Vivek Y Reddy
Journal:  Circulation       Date:  2021-04-06       Impact factor: 29.690

Review 3.  Overview of the Food and Drug Administration circulatory system devices panel meetings on WATCHMAN left atrial appendage closure therapy.

Authors:  Ron Waksman; Lakshmana K Pendyala
Journal:  Am J Cardiol       Date:  2014-11-12       Impact factor: 2.778

4.  Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial.

Authors:  Roberto Galea; Federico De Marco; Nicolas Meneveau; Adel Aminian; Frédéric Anselme; Christoph Gräni; Adrian T Huber; Emmanuel Teiger; Xavier Iriart; Flora Babongo Bosombo; Dik Heg; Anna Franzone; Pascal Vranckx; Urs Fischer; Giovanni Pedrazzini; Francesco Bedogni; Lorenz Räber; Marco Valgimigli
Journal:  Circulation       Date:  2021-11-06       Impact factor: 29.690

5.  Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry.

Authors:  Douglas Darden; Thao Duong; Chengan Du; Muhammad Bilal Munir; Frederick T Han; Ryan Reeves; Jacqueline Saw; Emily P Zeitler; Sana M Al-Khatib; Andrea M Russo; Karl E Minges; Jeptha P Curtis; James V Freeman; Jonathan C Hsu
Journal:  JAMA Cardiol       Date:  2021-11-01       Impact factor: 30.154

6.  Incidence of pericardial effusion after left atrial appendage closure: The impact of underlying heart rhythm-Data from the EWOLUTION study.

Authors:  Boris Schmidt; Timothy R Betts; Horst Sievert; Martin W Bergmann; Stephan Kische; Evgeny Pokushalov; Thomas Schmitz; Felix Meincke; Patrizio Mazzone; Kenneth M Stein; Hüseyin Ince; Lucas V A Boersma
Journal:  J Cardiovasc Electrophysiol       Date:  2018-05-21

7.  Device-Related Thrombus After Left Atrial Appendage Closure.

Authors:  Srinivas R Dukkipati; Saibal Kar; David R Holmes; Shephal K Doshi; Vijendra Swarup; Douglas N Gibson; Brijeshwar Maini; Nicole T Gordon; Michael L Main; Vivek Y Reddy
Journal:  Circulation       Date:  2018-08-28       Impact factor: 29.690

8.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.

Authors:  David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

9.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.

Authors:  David R Holmes; Vivek Y Reddy; Zoltan G Turi; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Christopher M Mullin; Peter Sick
Journal:  Lancet       Date:  2009-08-15       Impact factor: 79.321

10.  Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial.

Authors:  Dhanunjaya Lakkireddy; David Thaler; Christopher R Ellis; Vijendra Swarup; Lars Sondergaard; John Carroll; Michael R Gold; James Hermiller; Hans-Christoph Diener; Boris Schmidt; Lee MacDonald; Moussa Mansour; Brijeshwar Maini; Laura O'Brien; Stephan Windecker
Journal:  Circulation       Date:  2021-08-30       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.